Medtronic received information via literature regarding an evaluation of the outcomes in patients with aortic stenosis who underwent aortic root replacement using the freestyle bioprosthesis.All data were retrospectively collected from a single center between 2011 and 2017.The study population included 294 patients (predominantly male; mean age 68 years; 93% white).Of those, all were implanted with medtronic freestyle bioprosthetic valves.No serial numbers were provided.Among all patients, the mortality rate within 30 days, 1 year, and 5 years post implant were 7.1%, 13.9%, and 23.7%, respectively.Based on the available information, medtronic product was not directly associated with the deaths.Among all patients, adverse events included: new permanent pacemaker implantation, stroke, deep sternal wound infection, post-operative sepsis, surgical re-exploration due to mediastinal bleeding, reoperation due to endocarditis, bleeding requiring blood transfusion, new-onset atrial fibrillation, and hospital re-admission for congestive heart failure.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|